Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | RGS12 | O14924 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16906818 | 0.85 | MEN1 (0.46) | MEN1KMT2AKDM4ELMNATSHR | |
| SCHEMBL10914798 | 0.83 | MEN1 (0.62) | MEN1KMT2AKDM4ELMNATSHR | |
| SCHEMBL1426164 | 0.83 | GRIN2D (0.49) | MEN1KMT2AKDM4ETSHREGFR | |
| SCHEMBL18500620 | 0.82 | MEN1 (0.61) | MEN1KMT2AKDM4ELMNATSHR | |
| SCHEMBL12368473 | 0.82 | MEN1 (0.61) | MEN1KMT2AKDM4ELMNATSHR | |
| SCHEMBL16838141 | 0.81 | TSHR (0.42) | MEN1KMT2AKDM4ELMNATSHR | |
| SCHEMBL17295589 | 0.80 | TSHR (0.48) | MEN1KMT2ALMNATSHREGFR | |
| SCHEMBL9334664 | 0.79 | UGT2B7 (0.56) | MEN1KMT2AKDM4ELMNAUGT2B7 | |
| SCHEMBL2812852 | 0.79 | UGT2B7 (0.56) | MEN1KMT2AKDM4ELMNAUGT2B7 | |
| SCHEMBL9331659 | 0.79 | UGT2B7 (0.56) | MEN1KMT2AKDM4ELMNAUGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185547-B1 | IMIDAZOLONE DERIVATIVES, PREPARATION METHOD THEREOF AND BIOLOGICAL USE OF SAME | UNIV RENNES (FR) | 2017-07-19 | — | — | EP | disclosed |
| US-8563588-B2 | Imidazolone derivatives, method for the preparation thereof and biological applications | UNIVERSITE DE RENNES 1 (FR) | 2013-10-22 | — | — | US | disclosed |
| US-7998987-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-16 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100216855-A1 | IMIDAZAOLONE DERIVATIVES,PREPARATION THEREOF AND BIOLOGICAL USE OF SAME | UNIVERSITE DE RENNES (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-07-29 | — | — | US | disclosed |
| US-7728017-B2 | Inhibitors of c-Met and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| US-4464366-A | Cephem compounds having a terminal aminocarboxylic acid grouping and containing an azacyclyl(thio)ureido group | CIBA GEIGY CORPORATION (US) | 1984-08-07 | — | — | US | disclosed |
| EP-0031794-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | CIBA-GEIGY AG (CH) | 1981-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216855-A1 | IMIDAZAOLONE DERIVATIVES,PREPARATION THEREOF AND BIOLOGICAL USE OF SAME | NR0B2, HRH1, HRH2 | MEN1 576/4885KMT2A 4247/4885KDM4E 4226/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | MEN1 3603/4885KMT2A 1703/4885KDM4E 558/4885 |
| US-20100190774-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, HGF, ABL1 | MEN1 140/4885KMT2A 679/4885KDM4E 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.